Vertex Pharmaceuticals Stock Forecast, Price & News

Vertex Pharmaceuticals' stock was trading at $220.34 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, VRTX shares have decreased by 4.0% and is now trading at $211.58.
View which stocks have been most impacted by COVID-19.

29 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vertex Pharmaceuticals in the last year. There are currently 8 hold ratings, 20 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Vertex Pharmaceuticals.

Vertex Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, October 29th 2020.
View our earnings forecast for Vertex Pharmaceuticals.

Vertex Pharmaceuticals will be holding an earnings conference call on Thursday, October 29th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) announced its quarterly earnings data on Thursday, July, 30th. The pharmaceutical company reported $2.61 earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of $1.75 by $0.86. The pharmaceutical company had revenue of $1.52 billion for the quarter, compared to the consensus estimate of $1.41 billion. Vertex Pharmaceuticals had a net margin of 38.51% and a return on equity of 28.55%.
View Vertex Pharmaceuticals' earnings history.

Vertex Pharmaceuticals announced that its Board of Directors has authorized a share buyback program on Wednesday, July 31st 2019, which authorizes the company to repurchase $500,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization authorizes the company to repurchase up to 1.2% of its shares through open market purchases. Shares repurchase programs are usually an indication that the company's board of directors believes its shares are undervalued.

Vertex Pharmaceuticals updated its FY 2020 After-Hours earnings guidance on Thursday, July, 30th. The company provided EPS guidance of for the period. The company issued revenue guidance of $5.7-5.9 billion, compared to the consensus revenue estimate of $5.73 billion.

29 analysts have issued 1-year target prices for Vertex Pharmaceuticals' stock. Their forecasts range from $230.00 to $340.00. On average, they anticipate Vertex Pharmaceuticals' share price to reach $294.00 in the next year. This suggests a possible upside of 39.0% from the stock's current price.
View analysts' price targets for Vertex Pharmaceuticals.

Vertex Pharmaceuticals saw a decrease in short interest in September. As of September 15th, there was short interest totaling 3,040,000 shares, a decrease of 9.3% from the August 31st total of 3,350,000 shares. Based on an average daily trading volume, of 1,320,000 shares, the days-to-cover ratio is presently 2.3 days.
View Vertex Pharmaceuticals' Short Interest.

Some companies that are related to Vertex Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), Immunomedics (IMMU), Incyte (INCY), Exact Sciences (EXAS), Alnylam Pharmaceuticals (ALNY), BioMarin Pharmaceutical (BMRN), Repligen (RGEN), Neurocrine Biosciences (NBIX), Exelixis (EXEL) and Ionis Pharmaceuticals (IONS).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Vertex Pharmaceuticals investors own include NVIDIA (NVDA), Companhia de Saneamento Básico do Estado de São Paulo - SABESP (SBS), Alibaba Group (BABA), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Micron Technology (MU), salesforce.com (CRM), Netflix (NFLX), Intel (INTC) and Paypal (PYPL).

Vertex Pharmaceuticals trades on the NASDAQ under the ticker symbol "VRTX."

Vertex Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Candriam Luxembourg S.C.A. (0.21%), PGGM Investments (0.11%), Envestnet Asset Management Inc. (0.07%), Welch & Forbes LLC (0.07%), Peregrine Capital Management LLC (0.05%) and Retirement Systems of Alabama (0.05%). Company insiders that own Vertex Pharmaceuticals stock include Amit Sachdev, Bruce I Sachs, Charles F Wagner Jr, David Altshuler, Jeffrey M Leiden, Margaret G Mcglynn, Michael Parini, Ourania Tatsis, Paul M Silva, Reshma Kewalramani, Sangeeta N Bhatia, Stuart A Arbuckle, William D Young and Yuchun Lee.
View institutional ownership trends for Vertex Pharmaceuticals.

VRTX stock was sold by a variety of institutional investors in the last quarter, including Rhenman & Partners Asset Management AB, Nisa Investment Advisors LLC, Crossmark Global Holdings Inc., Standard Life Aberdeen plc, Redpoint Investment Management Pty Ltd, State of Alaska Department of Revenue, USA Financial Portformulas Corp, and Avantax Advisory Services Inc.. Company insiders that have sold Vertex Pharmaceuticals company stock in the last year include Amit Sachdev, Bruce I Sachs, Charles F Wagner Jr, David Altshuler, Jeffrey M Leiden, Michael Parini, Ourania Tatsis, Paul M Silva, Reshma Kewalramani, Sangeeta N Bhatia, Stuart A Arbuckle, William D Young, and Yuchun Lee.
View insider buying and selling activity for Vertex Pharmaceuticals.

VRTX stock was acquired by a variety of institutional investors in the last quarter, including PGGM Investments, Adams Diversified Equity Fund Inc., Envestnet Asset Management Inc., Forsta AP Fonden, Candriam Luxembourg S.C.A., Canal Capital Management LLC, Broadleaf Partners LLC, and CHURCHILL MANAGEMENT Corp.
View insider buying and selling activity for Vertex Pharmaceuticals.

Shares of VRTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of VRTX stock can currently be purchased for approximately $211.58.

Vertex Pharmaceuticals has a market capitalization of $55.11 billion and generates $4.16 billion in revenue each year. The pharmaceutical company earns $1.18 billion in net income (profit) each year or $4.29 on an earnings per share basis. Vertex Pharmaceuticals employs 3,000 workers across the globe.

The official website for Vertex Pharmaceuticals is www.vrtx.com.

Vertex Pharmaceuticals' mailing address is 50 NORTHERN AVENUE, BOSTON MA, 02210. The pharmaceutical company can be reached via phone at 617-341-6100 or via email at [email protected]